Drug:
Reaction: ASTHMA
20260101 - 20261231
No. 1301 - 1400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1301 | 26734866 |
US |
16 | 1 |
Injection site pain, Asthma, Meniscus removal, Depression, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, ALBUTEROL SULFATE, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, BENZTROPINE MESYLATE, BENZTROPINE, CLINDAMYCIN HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LITHIUM CARBONATE, METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ONDANSETRON HYDROCHLORIDE, PREDNISONE, INFLIXIMAB, CETIRIZINE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE, LITHIUM CARBONATE, LUMATEPERONE, |
||||
| 1302 | 26734875 |
US |
57 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1303 | 26734880 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, DULOXETINE HYDROCHLORIDE, DULOXETINE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE, ESOMEPRAZOLE MAGNESIUM DIHYDRATE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, BENRALIZUMAB, FOLLITROPIN, LOSARTAN POTASSIUM, LOSARTAN, ESZOPICLONE, |
||||
| 1304 | 26734900 |
US |
10 | 1 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1305 | 26734959 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, TIRZEPATIDE, |
||||
| 1306 | 26734981 |
CN |
4 | 1 |
Tracheitis, Asthma, Cough, |
||||
DUPILUMAB, |
||||
| 1307 | 26734993 |
US |
66 | 1 |
Nasopharyngitis, Asthma, |
||||
DUPILUMAB, |
||||
| 1308 | 26734997 |
US |
57 | 1 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1309 | 26735039 |
US |
1 | |
Injection site pain, Asthma, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ROSUVASTATIN, FLUTICASONE PROPIONATE, MAGNESIUM, MONTELUKAST SODIUM, MONTELUKAST, ORAL SEMAGLUTIDE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VITAMIN E, CETIRIZINE HYDROCHLORIDE, |
||||
| 1310 | 26735058 |
US |
55 | 2 |
Asthma, Headache, Paranasal sinus discomfort, Dyspnoea, Wheezing, Nasopharyngitis, Hypersensitivity, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 1311 | 26735123 |
US |
45 | 2 |
Nasal polyps, Product dose omission issue, Nasal congestion, Asthma, |
||||
DUPILUMAB, |
||||
| 1312 | 26735143 |
US |
42 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1313 | 26735149 |
US |
8 | 1 |
Viral infection, Nasopharyngitis, Asthma, |
||||
DUPILUMAB, |
||||
| 1314 | 26735221 |
US |
39 | 2 |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1315 | 26735229 |
US |
57 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1316 | 26735268 |
US |
2 | |
Asthma, Illness, Product dose omission issue, Product prescribing issue, Headache, Chest pain, |
||||
DUPILUMAB, |
||||
| 1317 | 26735336 |
US |
1 | |
Asthma, |
||||
DUPILUMAB, |
||||
| 1318 | 26735341 |
US |
2 | |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1319 | 26735370 |
US |
49 | 1 |
Asthma, Cough, |
||||
DUPILUMAB, |
||||
| 1320 | 26735459 |
US |
36 | 1 |
Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1321 | 26735462 |
US |
67 | 2 |
Hospitalisation, Asthma, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1322 | 26735482 |
US |
57 | 2 |
Illness, Bronchitis, Asthma, |
||||
DUPILUMAB, |
||||
| 1323 | 26735558 |
US |
5 | 2 |
Pneumonia, Asthma, Illness, Oxygen saturation decreased, Product use issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1324 | 26735563 |
US |
54 | 1 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1325 | 26735621 |
US |
69 | 2 |
Asthma, Product dose omission issue, Oral herpes, Dry eye, Arthralgia, Oropharyngeal pain, Insomnia, Injection site pain, Injection site erythema, Injection site irritation, |
||||
DUPILUMAB, |
||||
| 1326 | 26735626 |
US |
1 | |
Infection, Condition aggravated, Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1327 | 26735669 |
US |
61 | 2 |
Stress, Psychomotor hyperactivity, Joint swelling, Arthralgia, Asthma, |
||||
DUPILUMAB, |
||||
| 1328 | 26735675 |
US |
13 | 2 |
Pneumonia, Rhinitis allergic, Asthma, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1329 | 26735738 |
US |
63 | 2 |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, ALBUTEROL SULFATE AND BUDESONIDE, AZELASTINE HYDROCHLORIDE, AZELASTINE, DAPAGLIFLOZIN, MONTELUKAST SODIUM, MONTELUKAST, ORAL SEMAGLUTIDE, OLOPATADINE HYDROCHLORIDE, ROSUVASTATIN CALCIUM, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, VALSARTAN, VALSARTAN ORAL, |
||||
| 1330 | 26735742 |
US |
49 | 2 |
Cough, Asthma, Dyspnoea, |
||||
DUPILUMAB, |
||||
| 1331 | 26735758 |
US |
66 | 2 |
Pneumonia, Asthma, |
||||
DUPILUMAB, |
||||
| 1332 | 26735784 |
US |
2 | |
Dyspnoea, Pain, Spinal pain, Asthma, Drug hypersensitivity, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 1333 | 26735795 |
US |
68 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1334 | 26735865 |
US |
8 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1335 | 26735874 |
US |
56 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1336 | 26735957 |
US |
2 | |
Skin discolouration, Dry skin, Skin fissures, Skin swelling, Skin exfoliation, Dyshidrotic eczema, Asthma, Condition aggravated, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 1337 | 26735962 |
US |
44 | 2 |
Nasopharyngitis, Asthma, |
||||
DUPILUMAB, ALBUTEROL SULFATE AND BUDESONIDE, BACLOFEN, DICYCLOMINE HYDROCHLORIDE, FLUTICASONE PROPIONATE, LEVALBUTEROL HYDROCHLORIDE, LIOTHYRONINE SODIUM, MECLIZINE HYDROCHLORIDE, MECLIZINE, MECLIZINE HYDROCLORIDE, PSYLLIUM HUSK, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, PANTOPRAZOLE SODIUM, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, LEVOTHYROXINE SODIUM, LEVOCETIRIZINE DIHYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, |
||||
| 1338 | 26735987 |
US |
1 | |
Asthma, |
||||
DUPILUMAB, |
||||
| 1339 | 26736033 |
US |
62 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1340 | 26736077 |
US |
51 | 2 |
Cough, Chills, Pyrexia, COVID-19, Asthma, |
||||
EVOLOCUMAB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LOSARTAN POTASSIUM, LOSARTAN, MONTELUKAST SODIUM, MONTELUKAST, AZITHROMYCIN DIHYDRATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, ALBUTEROL SULFATE, BUDESONIDE AND FORMOTEROL FUMARATE, |
||||
| 1341 | 26733079 |
CN |
69 | 1 |
Asthma, Herpes zoster, Mouth ulceration, |
||||
MEPOLIZUMAB, |
||||
| 1342 | 26727920 |
EU |
44 | 1 |
COVID-19 pneumonia, COVID-19, Acute respiratory failure, Post-acute COVID-19 syndrome, Asthma, Periarthritis, Dyspnoea, |
||||
VALSARTAN, VALSARTAN ORAL, SECUKINUMAB, IVABRADINE, DAPAGLIFLOZIN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, SITAGLIPTIN, |
||||
| 1343 | 26728834 |
CA |
59 | 2 |
Pneumonia, Asthma, Cough, Dyspnoea, Chest pain, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, PREDNISONE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, MONTELUKAST SODIUM, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, ALBUTEROL, ZALEPLON, LANSOPRAZOLE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ORAL SEMAGLUTIDE, |
||||
| 1344 | 26728895 |
US |
76 | 2 |
Eye pruritus, Memory impairment, Asthma, Therapeutic response shortened, Inappropriate schedule of product administration, Neuromyopathy, Antinuclear antibody positive, |
||||
BENRALIZUMAB, BENRALIZUMAB, |
||||
| 1345 | 26728908 |
EU |
59 | 2 |
Polyp, Asthma, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 1346 | 26729147 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, |
||||
| 1347 | 26729181 |
US |
24 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1348 | 26729231 |
US |
52 | 2 |
Abdominal discomfort, Asthma, Injection site bruising, Upper respiratory tract infection, Cough, Nasal congestion, Rhinorrhoea, |
||||
DUPILUMAB, APREMILAST, ALBUTEROL SULFATE, MINOCYCLINE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BENZOYL PEROXIDE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, MAGNESIUM, PERFLUOROHEXYLOCTANE, MONTELUKAST SODIUM, MONTELUKAST, FAMOTIDINE, BECLOMETHASONE DIPROPIONATE HFA, GUSELKUMAB, GUSELKUMAB, TRETINOIN, ERGOCALCIFEROL, LIFITEGRAST, LIFITEGRAST, MINOCYCLINE, GUSELKUMAB, MAGNESIUM, |
||||
| 1349 | 26729281 |
US |
2 | |
Asthma, Aphonia, Upper-airway cough syndrome, Cough, Productive cough, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1350 | 26729422 |
EU |
65 | 2 |
Asthma, Chronic obstructive pulmonary disease, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRROLATE, BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRROLATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 1351 | 26729627 |
US |
1 | |
Meningitis, COVID-19, Nasopharyngitis, Chest discomfort, Asthma, Cough, |
||||
RAVULIZUMAB, |
||||
| 1352 | 26729674 |
US |
64 | 1 |
Asthma, Drug ineffective, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, CELECOXIB, DOXEPIN HYDROCHLORIDE, DOXEPN HYDROCHLORIDE, ESZOPICLONE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, |
||||
| 1353 | 26730054 |
CA |
65 | 2 |
Neutrophil count abnormal, Red cell distribution width abnormal, White blood cell disorder, White blood cells urine positive, Urine abnormality, Asthma, Therapeutic product effect incomplete, |
||||
MONTELUKAST SODIUM, MONTELUKAST, MONTELUKAST SODIUM, MONTELUKAST, CICLESONIDE, CICLESONIDE, CICLESONIDE, CICLESONIDE, CICLESONIDE, MEPOLIZUMAB, ALBUTEROL SULFATE, |
||||
| 1354 | 26730062 |
US |
40 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1355 | 26730336 |
US |
2 | |
Asthma, Illness, |
||||
DUPILUMAB, |
||||
| 1356 | 26730390 |
US |
||
Asthma, Product complaint, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 1357 | 26730393 |
GB |
33 | 2 |
Asthma, Memory impairment, Abdominal pain upper, Dyspnoea, Sleep disorder, Cough, Hiccups, Fatigue, |
||||
NAPROXEN, NAPROXEN SODIUM, LANSOPRAZOLE, |
||||
| 1358 | 26730536 |
EU |
66 | 1 |
Fibrin D dimer increased, C-reactive protein increased, Neutropenia, Chest pain, Neutropenic sepsis, Chills, Pyrexia, Lymphoedema, Polyneuropathy, Pain, Deep vein thrombosis, Leukopenia, Asthma, Vitamin D deficiency, Dizziness, Pulpitis dental, Anaemia, Oedema peripheral, Nausea, Drug therapeutic incompatibility, Product use in unapproved indication, |
||||
DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, PEGFILGRASTIM, PEGFILGRASTIM, PEGFILGRASTIM, PEGFILGRASTIM, PEGFILGRASTIM, PEGFILGRASTIM, PEGFILGRASTIM, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, ACYCLOVIR, BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, AMPHOTERICIN B, AMPHOTERICIN B, AMPHOTERICIN B, AMPHOTERICIN B, AMPHOTERICIN B, AMPHOTERICIN B, AMPHOTERICIN B, AMPHOTERICIN B, AMPHOTERICIN B, MESNA, MESNA, MESNA, MESNA, MESNA, MESNA, MESNA, MESNA, CLEMASTINE FUMARATE, CLEMASTINE FUMARATE, CLEMASTINE FUMARATE, CLEMASTINE FUMARATE, CLEMASTINE FUMARATE, CLEMASTINE FUMARATE, CLEMASTINE FUMARATE, CLEMASTINE FUMARATE, CLEMASTINE FUMARATE, ALLOPURINOL, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 1359 | 26730623 |
US |
56 | 2 |
Asthma, Therapeutic response shortened, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 1360 | 26731035 |
US |
79 | 2 |
Occipital lobe stroke, Atrial fibrillation, Asthma, Drug ineffective, Hypertension, Visual field defect, Epistaxis, Sleep disorder, Hyperlipidaemia, Gastrooesophageal reflux disease, Osteoporosis, Glucose tolerance impaired, Rhinitis allergic, Rubber sensitivity, |
||||
BENRALIZUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, OXYMETAZOLINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE, NASAL, OXYMETAZOLINE HCL, ARSENICUM ALBUM, EUPHORBIUM OFFICINARUM, HEPAR SULPHURIS CALCAREUM, HISTAMINUM, IODIUM, LYCOPODIUM, PULSATILLA, IPRATROPIUM BROMIDE, CLONIDINE, FLUTICASONE PROPIONATE, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, MONTELUKAST SODIUM, CETIRIZINE HYDROCHLORIDE, |
||||
| 1361 | 26731489 |
CA |
43 | 2 |
Abdominal pain, Abdominal pain upper, Adjustment disorder with depressed mood, Adverse drug reaction, Alopecia, Amnesia, Anti-cyclic citrullinated peptide antibody positive, Anxiety, Arthralgia, Arthropathy, Asthenia, Asthma, Autoimmune disorder, Back injury, Blepharospasm, Blister, Blood cholesterol increased, Bone erosion, Breast cancer stage II, Breast cancer stage III, Bursitis, C-reactive protein abnormal, Chest pain, Condition aggravated, Confusional state, Contraindicated product administered, Contusion, Depression, Deep vein thrombosis postoperative, Diarrhoea, Discomfort, Dizziness, Drug hypersensitivity, Drug ineffective, Drug intolerance, Dry mouth, Duodenal ulcer perforation, Dyspepsia, Fatigue, Ear pain, Epilepsy, Exostosis, Facet joint syndrome, Feeling hot, Folliculitis, Fibromyalgia, Frequent bowel movements, Gait disturbance, Gait inability, Gastrooesophageal reflux disease, General physical health deterioration, Glossodynia, Grip strength decreased, Hand deformity, Helicobacter infection, Hepatic enzyme increased, Hypercholesterolaemia, Hypertension, Hypoaesthesia, Ill-defined disorder, Impaired healing, Incorrect route of product administration, Inflammation, Infusion related reaction, Infusion site reaction, Injection site reaction, Injury, Intentional product misuse, Intentional product use issue, Irritable bowel syndrome, Joint range of motion decreased, Joint swelling, Laboratory test abnormal, Laryngitis, Lip dry, Liver function test increased, Live birth, Liver disorder, Maternal exposure during pregnancy, Normal newborn, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, APREMILAST, APREMILAST, APREMILAST, CANDESARTAN, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, LAMOTRIGINE, LAMOTRIGINE, LEFLUNOMIDE, ATOMOXETINE, AZATHIOPRINE, BOTULINUM TOXIN TYPE A, MEPOLIZUMAB, BUPRENORPHINE, BUPRENORPHINE, CELECOXIB, CELECOXIB, CELECOXIB, CELECOXIB, ACETAMINOPHEN AND CODEINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LANSOPRAZOLE, LISINOPRIL, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, QUETIAPINE FUMARATE, QUETIAPINE, RISEDRONATE SODIUM, SULFASALAZINE, FISH OIL, |
||||
| 1362 | 26731522 |
US |
24 | |
Asthma, Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, |
||||
| 1363 | 26731994 |
US |
2 | |
Asthma, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1364 | 26722823 |
US |
2 | |
Asthma, Pneumonia, |
||||
DEPEMOKIMAB, |
||||
| 1365 | 26722863 |
CA |
50 | |
Gastrooesophageal reflux disease, Irritability, Malaise, Middle insomnia, Otitis media, Pneumonia, Sensitive skin, Sensitivity to weather change, Skin irritation, Fall, Asthma, Nerve injury, Concomitant disease aggravated, Vital capacity abnormal, Forced expiratory volume decreased, Lung diffusion test decreased, Oropharyngeal pain, Rash macular, Urticaria, Pruritus, Rash, Illness, Influenza like illness, Product availability issue, Product dose omission issue, Incorrect dose administered, Drug ineffective, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, FLUTICASONE FUROATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, DEXLANSOPRAZOLE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, PREDNISONE, ROSUVASTATIN CALCIUM, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, |
||||
| 1366 | 26722875 |
US |
2 | |
Asthma, Illness, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, |
||||
| 1367 | 26722985 |
CA |
57 | |
Arthritis, Asthma, Bladder disorder, Illness, Nasal mucosal discolouration, Pain in extremity, Peripheral swelling, Tenosynovitis, Urinary tract infection, Weight decreased, Respiratory tract congestion, Cough, Sinusitis, Drug hypersensitivity, Nasal congestion, Pain, Weight increased, Inappropriate schedule of product administration, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, GLYCOPYRROLATE, METHOTREXATE, METHOTREXATE SODIUM, QUETIAPINE FUMARATE, QUETIAPINE, CICLESONIDE, CICLESONIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE, ALBUTEROL SULFATE, |
||||
| 1368 | 26723085 |
US |
69 | 1 |
Productive cough, Incorrect dose administered, Hypersensitivity, Rhinorrhoea, Asthma, |
||||
TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO, |
||||
| 1369 | 26723104 |
US |
68 | 2 |
Asthma, Hypersensitivity, Upper-airway cough syndrome, Cough, Product dose omission issue, Product leakage, Stress, Device failure, |
||||
TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO, |
||||
| 1370 | 26723209 |
US |
2 | |
Hypersensitivity, Cough, Lacrimation increased, Asthma, Nasopharyngitis, Dysgeusia, Wrong technique in device usage process, Device malfunction, |
||||
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 1371 | 26723318 |
US |
2 | |
Stress, Asthma, Hypersensitivity, Needle issue, Device leakage, |
||||
TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO, |
||||
| 1372 | 26723331 |
US |
78 | 2 |
Asthma, Intentional dose omission, |
||||
BRENSOCATIB, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, BENZONATATE, GABAPENTIN, GUAIFENESIN, MONTELUKAST, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ALBUTEROL SULFATE, ALBUTEROL, IRBESARTAN, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, CALCIUM, MAGNESIUM OXIDE, EVOLOCUMAB, TEZEPELUMAB-EKKO, ASCORBIC ACID, ERGOCALCIFEROL, ZINC SULFATE, ZINC SULFATE INJECTION,, ZINC SULFATE INJECTION, |
||||
| 1373 | 26723785 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, DUPILUMAB, ADALIMUMAB, |
||||
| 1374 | 26723795 |
US |
49 | 2 |
Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1375 | 26723801 |
US |
52 | 2 |
Asthma, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 1376 | 26723811 |
CA |
60 | 2 |
Asthma, Dyspnoea, Cough, |
||||
DUPILUMAB, DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL SULFATE, PREDNISONE, MONTELUKAST SODIUM, |
||||
| 1377 | 26723828 |
CN |
16 | 1 |
Pneumonia, Asthma, Seasonal allergy, |
||||
DUPILUMAB, DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 1378 | 26723957 |
US |
60 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1379 | 26723971 |
US |
1 | |
Eczema, Asthma, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1380 | 26724225 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, |
||||
| 1381 | 26724227 |
US |
6 | 2 |
Asthma, Skin ulcer, Eczema, |
||||
DUPILUMAB, |
||||
| 1382 | 26724229 |
US |
37 | 2 |
Asthma, Product dose omission issue, Injection site urticaria, Injection site discolouration, Injection site swelling, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 1383 | 26724255 |
US |
54 | 1 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1384 | 26724340 |
US |
31 | 1 |
Dermatitis atopic, Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1385 | 26724349 |
US |
41 | 2 |
Bronchitis, Asthma, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 1386 | 26724356 |
US |
||
Asthma, |
||||
MEPOLIZUMAB, |
||||
| 1387 | 26724497 |
US |
31 | 2 |
Asthma, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 1388 | 26724516 |
US |
56 | 2 |
Dyspnoea, Secretion discharge, Asthma, |
||||
DUPILUMAB, |
||||
| 1389 | 26724586 |
US |
15 | 1 |
Asthma, Cough, Wheezing, Drainage, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 1390 | 26724640 |
US |
2 | |
Asthma, Drug hypersensitivity, Therapy change, |
||||
BENRALIZUMAB, BENRALIZUMAB, |
||||
| 1391 | 26724888 |
US |
45 | 2 |
Bone pain, Pain, Asthma, Intentional dose omission, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1392 | 26724919 |
US |
79 | 1 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1393 | 26724980 |
US |
42 | 2 |
Asthma, Product administered at inappropriate site, |
||||
DUPILUMAB, |
||||
| 1394 | 26724987 |
US |
74 | 2 |
Asthma, Dyspnoea, |
||||
DUPILUMAB, |
||||
| 1395 | 26725920 |
US |
48 | 1 |
Asthma, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1396 | 26725922 |
US |
61 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1397 | 26726227 |
US |
36 | 2 |
Ageusia, Anosmia, Nasal congestion, Dyspnoea, Asthma, Bronchitis, Intentional dose omission, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1398 | 26726262 |
US |
10 | 1 |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1399 | 26726291 |
US |
56 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1400 | 26726373 |
US |
65 | 1 |
Asthma, Inappropriate schedule of product administration, Injection site pain, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30